innoscripta Shares Rebound 9% as Management Counters Tax Probe Fallout

innoscripta SE closed up 9.0% at EUR 41.05 after touching a 52-week low of EUR 31.05, as a tax probe and Warburg's suspended rating keep sentiment divided.

innoscripta SE shares closed Friday's session at EUR 41.05, a gain of 9.0%, after a turbulent week that saw the stock touch a fresh 52-week low of EUR 31.05 earlier in the day. The recovery came alongside a company statement aimed at calming investor nerves, though market participants remain divided on whether the rebound marks a durable floor or merely a technical bounce.

At the heart of the turmoil are searches carried out Thursday at innoscripta premises in Munich and Tutzing, along with other group subsidiaries. Investigators acted on two warrants issued by the Amtsgericht Schwäbisch Gmünd dated 3 August and 15 September. The probe is a tax-criminal investigation centred on suspected aiding and abetting in obtaining unjustified tax benefits tied to individual clients' research allowance applications.

Management Pushes Back

innoscripta sought to draw a line under the uncertainty, stating that day-to-day operations continue without restriction and that, based on current knowledge, no transactions from the present financial year are affected by the authorities' actions. The company also pledged full cooperation with investigators.

In a further effort to engage shareholders, management said it would invite investors to a personal presentation of the group's products, with dates to be announced shortly. The statement was published in direct response to the unease that had weighed on the stock.

A Week of Sharp Swings

The ad-hoc disclosure of the searches on Thursday triggered heavy selling, driving the shares to their new annual low before buyers stepped back in. No specific company-level catalyst was identified for Friday's intraday turnaround, leaving the market to debate whether management's reassurances can permanently break the selling pressure. The gap between the authorities' allegations and the company's insistence that business is running normally now defines the picture.

Much depends on whether the allegations prove confined to past periods. Any financial burden or restriction on the research allowance business could erode confidence. Until concrete investigation results emerge, market participants are expected to track the company's next moves with considerable vigilance.

Warburg Pulls Its Rating

Caution is also building on the analyst side. According to media reports, Warburg Research suspended both its price target and its rating for innoscripta, citing the difficulty of reliably assessing the consequences of the ongoing investigations.

The bull case rests largely on management's immediate response. Should it be confirmed that past matters carry no material repayments or penalties, the operating earnings power of the current year would remain intact. Roughly a month ago, innoscripta reported first-half revenue growth and expansion into Austria, and also recorded an insider purchase by a major shareholder. If the company can quickly dispel the allegations, the recent countermove could mark the start of a technical bottoming-out.

Reputation Risk in Focus

Against that stands a pronounced risk scenario. Investigations into suspected aiding and abetting of tax offences threaten not only potential payment obligations but, above all, reputational damage. The new research allowance business is built on trust, meaning that even the launch of such proceedings could deter clients.

Should the probe drag on or spread to additional business areas, significant strain on the balance sheet would follow. In that case, earlier growth drivers would lose relevance, as possible fines and legal advisory costs would eat into liquidity.

Chart Support in the Spotlight

The technical and fundamental backdrop will prove decisive. As long as the recently marked low of EUR 31.05 holds, there is room for the stock to consolidate at a reduced level. A breach of that support on fresh details from the public prosecutor's investigation, however, would risk a continuation of the downtrend. The next concrete catalyst is the review of the allegations announced by innoscripta, along with an initial official assessment of possible financial burdens. Only once reliable findings are available can the scale of the authorities' actions be properly quantified.